Full results from the OPTIMIZE study, due to be completed in August 2021, are forthcoming.
Unlike phosphate binders, tenapanor decreases paracellular phosphate absorption in the intestine.
In a small Canadian study, investigators found that patients switched from conventional to in-center nocturnal hemodialysis experience improvements in various measures of health-related quality of life, especially mental health.
Investigators ruled out hyperphosphatemia and SHPT as confounders in each other’s association with CKD outcomes.
Trial investigated lanthanum carbonate, which has been used worldwide to treat hyperphosphatemia and has been reported to delay vascular calcification.
Maintaining the patency of the AVF may be challenging in patients with hyperphosphatemia, study findings suggest.
Circulating FGF23 starts to rise in early stage CKD before the development of other abnormalities such as high parathyroid and phosphate levels and low calcium and 1,25(OH)2D levels.
Investigators found a U-shaped relationship between serum intact parathyroid hormone levels and death risk in Chinese patients initiating hemodialysis.
Tenapanor inhibits the sodium hydrogen exchanger 3 (NHE3), reducing paracellular uptake of phosphate in the intestine.
Nicotinamide modulates expression of the sodium-dependent phosphate cotransporter 2b and thereby may inhibit intestinal phosphate absorption, according to investigators.